This job has expired

You will need to login before you can apply for a job.

Process Development Scientist I, mRNA

Precision BioSciences, Inc.
Durham, NC
Start date
Sep 21, 2022

View more

You need to sign in or create an account to save a job.

Job Details



Precision Biosciences is currently seeking to fill the role of Process Development Scientist I, mRNA.  The Process Development Scientist I will be a critical part of the team charged with developing a world-class manufacturing process for making mRNA-based active pharmaceutical ingredient (API) for cell and gene therapies.  The candidate’s responsibilities will be in all aspects of process development, including mRNA sequence optimization, in-vitro transcription (IVT), downstream purification, analytical testing of drug substance.


**Please note, Precision BioSciences mandates COVID-19 vaccination of all employees. Accommodations may be made in accordance with applicable law.


Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position.  This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.


  • Design/optimize mRNA constructs in collaboration with research to improve stability and translational efficiency
  • Execute preclinical and proof-of-concept animal studies in collaboration with in vivo team and external CROs
  • Develop downstream purification operations for DNA template and mRNA appropriate to the scale of the process
  • Develop biochemical, cell-based and chromatographic assays in collaboration with the analytical team for raw materials characterization, in-process and final product testing
  • Maintain accurate and complete lab records and other documentation
  • Write and review technical and regulatory documents including ELN entries, batch records, work instructions, SOPs, and technical reports
  • Manage final product, process intermediate, and raw material inventories



The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.



  • PhD in Molecular Biology, Biochemistry, Chemistry or related field or equivalent combination of education and experience
  • Strong understanding of in-vitro transcription-based mRNA synthesis and nucleic acids chemistry
  • Experience with plasmid design, sequence analysis and molecular cloning
  • Knowledge of AKTA / Agilent Chromatography systems and standard purification techniques (AEX, SEC, HIC, membrane filtration, depth filtration, tangential flow filtration)
  • Experience with standard molecular biology skills, including running Agarose, denaturing PAGE gels, ELISA, UV/Vis testing, qPCR and protein testing
  • Experience with DOE methodology for process improvement
  • Strong communication skills, both written and verbal
  • Ability to mentor junior associates and engineers
  • Software skills including Excel, Word, and statistical software
  • The ability to work both independently and in a collaborative environment
  • Ability to define problems, collect and analyze data, establish facts and draw valid conclusions



  • Experience using SnapGene, VectorNTI


Travel Requirements

  • Minimal travel is anticipated for this role. 


  • This is a lab-based position located at the main headquarters in downtown Durham, NC.



Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs.  For additional information, please visit www.


Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.


Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Find Us
302 East Pettigrew Street
North Carolina
United States
You need to sign in or create an account to save a job.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert